INTRODUCTION
Cholangiocarcinoma is the second most common primary hepatobiliary malignancy originating from the epithelium of the intrahepatic, perihilar, or extrahepatic bile ducts, with the frequencies of 5 to 30%, 40 to 50%, and 20 to 30%, respectively [1] [2] [3] [4] [5] . The incidence of intrahepatic cholangiocarcinoma is increasing worldwide, especially in Asia, while the incidence of extrahepatic cholangiocarcinoma is somewhat stable or declining [6] [7] [8] [9] [10] [11] . Surgical resection remains the only curative treatment option for cholangiocarcinoma, but most patients are far advanced at the time of presentation, which leads to a poor survival outcome [12] [13] [14] [15] [16] . In addition, spreading widely through bile ductules and extensive invasion to adjacent organs, cholangiocarcinoma has frequent locoregional or distant recurrences via lymphatic chains or hematogenous metastasis [4, 5, 12, 17, 18] . Kobayashi et al. [19] reported distant thesurgery.or.kr metastases were more common than locoregional recurrence after R0 resection in patients with perihilar cholangiocarcinoma.
The 5-year overall survival rate after surgical resection of cholangiocarinoma is reported to be 5 to 40%, and the median overall survival time and median recurrence-free survival time is 27 to 33 and 9 to 27 months, respectively [6] [7] [8] 10, 13, 15, [18] [19] [20] . Many published series have reported the risk factors for poor survival and recurrence; perineural invasion via lymphatic pathway and the proximity to the peripheral nerve plexus, presence of lymph node metastasis, poor differentiation, higher T stage, positive surgical resection margin and high level of carbohydrate antigen (CA) 19-9 [12, 15, 17, [19] [20] [21] . The recurrence sites vary from local or locoregional recurrence in abdominal cavity to distance metastasis including abdominal or chest wall, skeletal muscles, lung, bone or brain [1, 6, 5, 22, 23] .
Repeated hepatic resection for large, resectable tumors or radiofrequency ablation (RFA) for several small nodules have demonstrated their effectiveness on survival for the treatment of recurrent intrahepatic cholangiocarcinoma in some series [17, 18, 24] .
However, there is no large-scale series to verify beneficial effects in terms of survival through surgical treatments including other types of recurrent cholangiocarcinomas. Thus, we attempted to identify whether or not there is a survival benefit to patients with recurrent cholangiocarcinoma who had undergone surgical resection with curative intent according to the recurrent sites and the types of resection.
METHODS

Study patients
Nine hundred forty-nine patients who underwent surgical treatment for cholangiocarcinoma in a single institute between May 1995 and July 2010 were reviewed retrospectively based on electronic medical records with pathologic reports. They proved to be primary adenocarcinomas pathologically arising from the bile duct epithelium. With the exception of 28 patients who had palliative resection, 921 patients underwent curative-intent surgical resection (R0 = 830, R1 = 91).
Cholangiocarcinoma was classified according to the tumor location according to preoperative radiologic and final pathologic findings, which included intrahepatic (n = 226), perihilar (n = 222), and extrahepatic (n = 474). Cholangiocarcinoma of gallbladder was not included in this series. 74, 78 and 164 patients had recurrent diseases during the study period, respectively. These 316 patients were divided into the following 2 groups: patients who underwent surgical resection for recurrence (group A) and patients who were not treated (group B).
Initial procedures and managements
To the patients with intrahepatic cholangiocarcinomas, 
Types of treatment for recurrence
Patients were routinely followed in the outpatient department with CA 19-9 levels and abdominal con- The inclusion criteria for RFA generally followed the indications for hepatocellular carcinoma; ＜3 tumor lesions with a maximum diameter ＜3 cm, single nodular lesions with a maximum diameter ＜5 cm, no major vessel or bile duct involvement, and no uncorrectable coagulopathy [25] . The technical effectiveness was verified with a CT after 1 month with no residual unablated tumors.
Further hepatic resection was considered according to the anatomic location, size, and number of lesions when RFA could not be performed. Metastasectomy was considered for metastatic lesions of the abdominal wall, chest wall, peritoneum, and solitary pulmonary nodules.
Pylorus-preserving pancreaticoduodenectomy or Whipple's procedure was performed to treat locoregional recurrence after segmental bile duct resection for extrahepatic cholangiocarcinoma. 
Statistical analysis
RESULTS
Demographics
The median follow-up period was 21.8 months (range, 1.8 to 153.0 months) and the number of patients was 27 and 289 in group A and B, respectively. There were no statistical differences in gender, age and pre-operative carcinoembryonic antigen and CA 19-9 levels. In addition, tumor size, location, differentiation, radicality, the ratio of lymph node metastasis, tumor staging and time-to-recurrence did not have significant differences, except the rate of patients receiving adjuvant concurrent chemoradiotherapy, which was shown to be statistically higher in group A (P = 0.037, Table 1 ). ) Pancreaticoduodenectomy (8) Whipple's procedure (4), PPPD (4) Partial pancreatectomy (1) This patient previously underwent right trisegmentectomy due to hilar cholangiocarcinoma. After 14 months, he underwent intra-operative RFA due to second recurrence at hepatic resection margin Regional lymph node dissection (1) Intrahepatic cholangiocarcinoma with lymph node metastasis RFA (7) All were percutaneous RFA VATs-WR, video-assisted thoracic surgery-wedge resection, PPPD, pylorus-preserving pancreaticoduodenectomy, RFA, radiofrequency ablation.
Recurrence after surgical resection
a)
One patient underwent RFA after 2 months due to second hepatic recurrence.
b)
One patient underwent hepatic tumorectomy after 1 month due to second hepatic recurrence. Table 2 ).
The recurrent rate was highest after pancreaticoduodenectomy (37.0%) for extrahepatic cholangiocarcinoma.
The recurrent sites were as follows; solitary (n = 83) or multiple (n = 17) hepatic recurrence, locoregional recurrence except liver (n = 118), peritoneal seeding (n = 49), lung or pleura (n = 20), abdominal or chest wall (n = 7), bone (n = 5), brain (n = 2), supraclavicular lymph node (n = 2) and multiple site recurrence (n = 13). (Table 3 ). In the current study, we did not perform surgical resection or RFA for multiple hepatic metastatic lesions, and surgical procedures for peritoneal seeding, supraclavicular lymph node and bone or brain metastasis.
180, 80 and 56 patients had recurrence within 1 year, from 1 to 2 years, and above 2 years, respectively. During these periods, various treatments for recurrence were per- Fig. 1 . Overall survival rate after recurrence according to surgical treatment and concurrent chemoradiotherapy (CCRT) for recurrent cholangiocarcinoma (group A; patients treated surgically for recurrence, group B; patients not treated, P-value between the two groups = 0.001).
Group A (n = 27) Group B (n = 289) (2) 14.6-21.8 Multiple sites (11) 1.4-32.5 CCRT, concurrent chemoradiotherapy. Table 6 . Multivariate analysis of prognostic factors on overall survival after recurrence formed to 9.3%, 10.0% and 19.6% of the recurrent patients, respectively (Table 4) .
Overall survival and range of survival after recurrence
The median times to recurrence were 15.0 and 10.1 months in group A and B, respectively (P = 0.118). The median times from recurrence to surgical treatment for recurrent disease in group A was 27 days (range, 14 to 182 days). The median survival times after recurrence were 18.9 months (range, 1.7 to 101.8 months) and 7.7 months (range, 0.5 to 89.1 months) in group A and B, respectively.
The cumulative overall survival rate after recurrence was significantly higher in group A than group B (P = 0.001, Fig. 1 ). The additional chemoradiotherapy did not show significant survival benefits in either group. The beneficial effect of surgical treatment for recurrent disease with respect to the ranges of survival was remarkable in the case of locoregional recurrence except liver and abdominal or chest wall metastasis (Table 5) . Surgical resection for recurrent cholangiocarcinoma was identified as an independent prognostic factor on overall survival according to multivariate analysis (HR = 2.308, P = 0.025) ( Table 6 ).
DISCUSSION
The long-term survival outcomes of patients who un- In this series, the recurrence rate of cholangiocarcinoma showed 34.3%, and about 57% of recurrence occurred within 1 year. However, only 8.3% of patients with recurrence were treated surgically in this period, while 10.0% and 19.6% of patients were treated from 1 to 2 years and above 2 years, respectively. Thus, early surgical resection should be considered to acquire greater survival benefits.
There are some drawbacks in this retrospective study.
First, differences in the clinical course and pathogenesis among the three types of cholangiocarcinoma may exist.
But it was reported that there were no significant differences in clinical presentation, disease stage and survival between intra-and extra-hepatic cholangiocarcinoma [6] .
Second, a relatively smaller incidence of recurrence than in previous studies was identified. It might be influenced not by the development of the palliative treatment options, but also missed patients who were previously treated surgically. In fact, patients with cholangiocarcinoma have been increasing recently who were treated surgically or with RFA. Therefore, further follow-up studies for these patients are warranted to understand tumor biology and diverse patterns of tumor recurrence to make up for these limitations. Francis et al. [9] and Zhang et al. [4] introduced regulation of cholangiocarcinoma from a biologic point of view. Their reviews suggested that genetic hypermethylation, interleukin-6, growth factors, gastrointestinal hormones, neuroregulatory molecules, angiogenesis, or E-cadherin-mediated cell-to-cell adhesion expressed by the Slug gene are related to growth or invasiveness of the tumor. Third, although most of the clinicopathologic characteristics were similar in our two groups, the rate of patients who underwent adjuvant CCRT was higher in group A. This selection bias could be an interference factor in drawing our conclusion. Finally, overall survival has room for modification because the recurrence patterns between the two groups were not similar. Thus, further prospective controlled study is needed to overcome this limitation.
In conclusion, according to this large-series study in a 
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